GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » ROE % Adjusted to Book Value

CervoMed (CervoMed) ROE % Adjusted to Book Value : -18.99% (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is CervoMed ROE % Adjusted to Book Value?

CervoMed's ROE % for the quarter that ended in Dec. 2023 was -111.47%. CervoMed's PB Ratio for the quarter that ended in Dec. 2023 was 5.87. CervoMed's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -18.99%.

CervoMed ROE % Adjusted to Book Value Historical Data

The historical data trend for CervoMed's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CervoMed ROE % Adjusted to Book Value Chart

CervoMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -85.74 -30.79 -90.66 - -

CervoMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -115.44 26.37 -18.99

Competitive Comparison of CervoMed's ROE % Adjusted to Book Value

For the Biotechnology subindustry, CervoMed's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CervoMed's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CervoMed's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CervoMed's ROE % Adjusted to Book Value falls into.


CervoMed ROE % Adjusted to Book Value Calculation

CervoMed's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 5.87
=0.00%

CervoMed's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-111.47% / 5.87
=-18.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CervoMed ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of CervoMed's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

CervoMed (CervoMed) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
IMAB YS GOSS CYDY ACET OBIO PRQR ACHV RGLS RPTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
20 Park Plaza, Suite 424, Boston, MA, USA, 02216
Website
https://www.diffusionpharma.com
CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.
Executives
Frank Zavrl director C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Sylvie Gregoire director, 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner officer: Chief Financial Officer C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Kelly Blackburn officer: VP, Clinical Development C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John J Alam director, 10 percent owner, officer: CEO and President 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
Jill Davidson director 300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger officer: Chief Regulatory Officer 300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois director C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney director 1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
William Robert Elder officer: GC & Secretary 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr. director C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway officer: Chief Medical Officer 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth director DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902